Further studies are ongoing (Supplementary Table S1) and required to clarify its effects and applicability, as well as explore the properties of other prospective V2R antagonists that could potentially benefit a wider group of ADPKD patients. This evidence concerns the gene AVPR2 and autosomal dominant polycystic kidney disease.